Compile Data Set for Download or QSAR
Report error Found 174 Enz. Inhib. hit(s) with all data for entry = 9922
TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499334(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499388(4-((3-(5- (cyclopropylmethyl)isoxazol-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499334(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499324(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 50nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499313(4-((3-(6- (cydopropylmethoxy)pyridin-3- yl)phenoxy...)
Affinity DataIC50: 80nMMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499402(4-((3-(5-chloro-6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499401(tert-butyl 3-(((5-(3-((2-fluoro-4- ((methylsulfony...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499400(4-((3-(5-chloro-6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499399(4-((3-(6-(cyclopropylmethoxy)- 4-methylpyridin-3-y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499398(4-((3-(6-(cyclopropylmethoxy)- 4-methylpyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499397(4-((3-(6-(cyclopropylmethoxy)- 2-methylpyridin-3-y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499396(4-((3-(6-(cyclopropylmethoxy)- 5-methylpyridin-3-y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499395(4-((3-(6-(cyclopropylmethoxy)- 5-methylpyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499394(4-((3-(6-(cyclobutylmethoxy)-2- methylpyridin-3-yl...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499393(4-((3-cyano-5-(6- (cyclopropylmethoxy)pyridin-3- y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499392(4-((3-fluoro-5-(6- ((tetrahydrofuran-3- yl)methoxy...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499391(3-fluoro-N-(methylsulfonyl)-4- ((3-(6-((tetrahydro...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499390(4-((3-(6-(cyclopropylmethoxy)- 2-methylpyridin-3-f...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499389(4-((3-(6-(cyclopropylmethoxy)- 2-methylpyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499388(4-((3-(5- (cyclopropylmethyl)isoxazol-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499387(4-((3-(1-(cyclopropylmethyl)- 1H-pyrazol-3- yl)phe...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499418(4-((3-(6- (cyclopropylmethoxy)pyridin-2- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499417(6-((3-(6- (cyclobutylmethoxy)pyridin-3- yl)phenoxy...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499416(4-((3-(5- (cyclopropylmethoxy)pyridin-3- yl)-5-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499415(4-((3-(5- (cyclopropylmethoxy)pyridin-3- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499414(4-((3-(6- (cyclopropylmethoxy)pyridin-3- yl)-5-(py...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499413(4-((3-(6- (cyclopropylmethoxy) pyridin-3-yl)- 5-(1...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499412(4-((3-(6- (cyclopropylmethoxy) pyridin-3-yl)- 5-(p...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499411(4-(((5-(6- (cyclopropylmethoxy) pyridin-3-yl)- [1,...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499410(4-((3-(6-(cyclobutylmethoxy)-2- (hydroxymethyl)pyr...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499409(4-((3-(6-(cyclobutylmethoxy)-2- (hydroxymethyl)pyr...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499408(4-((3-(6-(cyclobutylmethoxy)-5- (hydroxymethyl)pyr...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499407(4-((3-(6-(cyclobutylmethoxy)-5- (hydroxymethyl)pyr...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499406(4-((3-(6-(cyclobutylmethoxy)-5- (hydroxymethyl)pyr...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499405(4-((3-(6-(cyclobutylmethoxy)-5- (hydroxymethyl)pyr...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499404(4-((3-(6-(cyclopropylmethoxy)-2- methylpyridin-3-y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499403(4-((3-(5-chloro-6- (cyclopropylmethoxy)pyridin-3- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499434(4-((3-(4- (cyclopropylmethoxy)pyridin-2- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499433(4-((3-(4- (cyclopropylmethoxy)pyridin-2- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499432(4-((3-(4- (cyclopropylmethoxy)pyridin-2- yl)-5-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499431(4-((3-(4-(cyclopropylmethoxy)-3- methylpyridin-2-y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499430(4-((3-(4-(cyclopropylmethoxy)-3- methylpyridin-2- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499429(4-((3-(5- (cyclopropylmethoxy)pyridin-2- yl)-5-flu...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499428(4-((3-(5- (cyclopropylmethoxy)pyridin-2- yl)phenox...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499427(4-((3-(5-(cyclobutylmethoxy)-3- methylpyridin-2- y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499426(4-((3-(5-(cyclopropylmethoxy)-3- methylpyridin-2- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499425(4-((3-(5-(cyclobutylmethoxy)-3- methylpyridin-2-yl...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499424(4-((3-(5-(cyclopropylmethoxy)-3- methylpyridin-2- ...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499423(4-((3-(5-(cyclopropylmethoxy)- 3-fluoropyridin-2-y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

TargetSodium channel protein type 9 subunit alpha(Human)
Raqualia Pharma

US Patent
LigandPNGBDBM499422(4-((3-(5-(cyclopropylmethoxy)- 3-fluoropyridin-2-y...)
Affinity DataIC50: 500nMAssay Description:This screen is used to determine the effects of compounds on human Nav1.7 channels, utilizing electrical field stimulation (EFS) system in 96-well pl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/28/2021
Entry Details
US Patent

Displayed 1 to 50 (of 174 total ) | Next | Last >>
Jump to: